JP2021515598A5 - - Google Patents
Info
- Publication number
- JP2021515598A5 JP2021515598A5 JP2020571330A JP2020571330A JP2021515598A5 JP 2021515598 A5 JP2021515598 A5 JP 2021515598A5 JP 2020571330 A JP2020571330 A JP 2020571330A JP 2020571330 A JP2020571330 A JP 2020571330A JP 2021515598 A5 JP2021515598 A5 JP 2021515598A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- domain
- nucleic acid
- endogenous
- recombinant nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641159P | 2018-03-09 | 2018-03-09 | |
| US62/641,159 | 2018-03-09 | ||
| PCT/US2019/021315 WO2019173693A1 (en) | 2018-03-09 | 2019-03-08 | Compositions and methods for tcr reprogramming using fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515598A JP2021515598A (ja) | 2021-06-24 |
| JP2021515598A5 true JP2021515598A5 (enExample) | 2022-03-16 |
Family
ID=67846339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571330A Withdrawn JP2021515598A (ja) | 2018-03-09 | 2019-03-08 | 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210361704A1 (enExample) |
| EP (1) | EP3765039A4 (enExample) |
| JP (1) | JP2021515598A (enExample) |
| KR (1) | KR20200130383A (enExample) |
| CN (1) | CN111954714A (enExample) |
| AU (1) | AU2019231792A1 (enExample) |
| BR (1) | BR112020018173A2 (enExample) |
| CA (1) | CA3093449A1 (enExample) |
| EA (1) | EA202092093A1 (enExample) |
| MX (1) | MX2020009371A (enExample) |
| SG (1) | SG11202008721SA (enExample) |
| WO (1) | WO2019173693A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| KR20210139472A (ko) * | 2019-04-11 | 2021-11-22 | 페이트 세러퓨틱스, 인코포레이티드 | 조작된 iPSC 및 면역 효과기 세포에서의 CD3 재구성 |
| WO2021035170A1 (en) * | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MX2022002984A (es) * | 2019-09-12 | 2022-06-16 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. |
| US20220387493A1 (en) * | 2019-11-06 | 2022-12-08 | Baylor College Of Medicine | Method for producing cytotoxic effector memory t-cells for car t-cell treatment of cancer |
| WO2021133959A2 (en) * | 2019-12-24 | 2021-07-01 | TCR2 Therapeutics Inc. | Compositions and methods for gamma delta tcr reprogramming using fusion proteins |
| CA3191448A1 (en) * | 2020-08-12 | 2022-02-17 | Migal Galilee Research Institute Ltd. | Alloreactive immune cell-distancing device and uses thereof for protecting donor-derived cells from allorejection |
| US20240117002A1 (en) * | 2020-12-23 | 2024-04-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN117480247A (zh) * | 2021-04-15 | 2024-01-30 | 恺兴生命科技(上海)有限公司 | 嵌合t细胞受体及其应用 |
| WO2023179795A1 (zh) * | 2022-03-25 | 2023-09-28 | 立凌生物制药(苏州)有限公司 | 一种快速且简便地获得正确配对tcr的方法以及获得的tcr |
| CN119487071A (zh) * | 2022-06-24 | 2025-02-18 | 北京可瑞生物科技有限公司 | 基于t细胞受体的双特异性多肽分子及其用途 |
| WO2024138181A2 (en) * | 2022-12-23 | 2024-06-27 | Tcrcure Biopharma Corp. | Engineered t cell receptors and engineered immune cells expressing the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003208839A1 (en) * | 2002-02-13 | 2003-09-04 | Micromet Ag | De-immunized (poly)peptide constructs |
| WO2011059836A2 (en) * | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| BR112014029417B1 (pt) * | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| PL3298033T5 (pl) * | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| WO2017214452A1 (en) * | 2016-06-08 | 2017-12-14 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| JP7291396B2 (ja) * | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| JP2020513754A (ja) * | 2016-12-21 | 2020-05-21 | ティーシーアール２ セラピューティクス インク． | がん治療用に操作されたｔ細胞 |
-
2019
- 2019-03-08 MX MX2020009371A patent/MX2020009371A/es unknown
- 2019-03-08 CA CA3093449A patent/CA3093449A1/en active Pending
- 2019-03-08 EP EP19763494.2A patent/EP3765039A4/en not_active Withdrawn
- 2019-03-08 KR KR1020207028766A patent/KR20200130383A/ko not_active Abandoned
- 2019-03-08 SG SG11202008721SA patent/SG11202008721SA/en unknown
- 2019-03-08 JP JP2020571330A patent/JP2021515598A/ja not_active Withdrawn
- 2019-03-08 EA EA202092093A patent/EA202092093A1/ru unknown
- 2019-03-08 WO PCT/US2019/021315 patent/WO2019173693A1/en not_active Ceased
- 2019-03-08 BR BR112020018173-0A patent/BR112020018173A2/pt not_active IP Right Cessation
- 2019-03-08 CN CN201980023038.1A patent/CN111954714A/zh active Pending
- 2019-03-08 AU AU2019231792A patent/AU2019231792A1/en not_active Abandoned
- 2019-03-08 US US16/979,380 patent/US20210361704A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515598A5 (enExample) | ||
| US11008376B2 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| JP2022130485A (ja) | 哺乳動物細胞における薬物リガンドの誘導による導入遺伝子の発現に対する感受性が増強されたキメラ転写因子バリアント | |
| JP7636650B2 (ja) | 二量体形成剤調節性免疫受容体複合体 | |
| JP2022530037A5 (enExample) | ||
| US20210361704A1 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| JP2022530037A (ja) | 融合タンパク質を使用するｔｃｒ再プログラミングのための組成物及び方法 | |
| JP2022548866A5 (enExample) | ||
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| CN114828862A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| WO2022232277A1 (en) | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH | |
| JP2024515181A5 (enExample) | ||
| JP2024501831A5 (enExample) | ||
| JP2022526720A5 (enExample) | ||
| WO2022192286A1 (en) | Compositions and methods for tcr reprogramming using fusion proteins and rna interference | |
| KR102764613B1 (ko) | NaPi2b 특이적 CAR-T를 포함하는 난소암 치료용 약학 조성물 | |
| WO2025117851A1 (en) | Meso-fap with adam17 inhibitor or itk inhibitor | |
| JP2026501830A (ja) | 遺伝子操作ｔ細胞 | |
| Torikai et al. | Engineering T Cells to target tumor cells | |
| Bridgeman et al. | T-Bodies: Antibody-Based Engineered T-Cell Receptors | |
| JP2024506647A5 (enExample) | ||
| HK40054580A (en) | Trifunctional t cell-antigen coupler and methods and uses thereof | |
| Abken | Es is as drop op op | |
| Torikai et al. | ENGINEERING IMMUNE CELLS FOR CANCER THERAPY |